Keywords: سارکوم نرم بافت; AEs; adverse events; EMT/MET; epithelial-mesenchymal transition/mesenchymal-epithelial transition; LPS; liposarcoma; LVEF; left ventricular ejection fraction; STS; soft-tissue sarcomas; Sarcoma; Metastatic disease; Chemotherapy; Epigenetics; Targeted ther